CADTH Canadian Drug Expert Committee recommendation : indication : for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprostene bunod (Vyzulta -- Bausch Health, Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Glaucoma.

Cost effectiveness.

Physical Description:

1 online resource

Edition:

First edition.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2019.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that latanoprostene bunod 0.24 mg/ml ophthalmic solution (Vyzulta) be reimbursed for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) only if the following conditions are met : Conditions for Reimbursement : Initiation criteria 1. Patient must be ≥ 18 years 2. Patient must have a documented diagnosis of open-angle glaucoma or ocular hypertensionin one or both eyes. Pricing condition: The cost of treatment with LBN ophthalmic 0.024% solution should not exceed the drug plan cost of treatment with the least costly alternative prostaglandin analogue (PGA) or least costly beta-blocker reimbursed for the treatment of open-angle glaucoma or ocular hypertension.

Notes:

Description based on publisher supplied metadata and other sources.